FOUND: 6 - You Need To See This

3 Biotech Stocks Set to Revolutionize Medicine

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To capitalize on the industry’s expansion, it could be wise to invest in fundamentally sound biotech stocks, Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which have the potential to revolutionize medicine. Read…

StockNews.com · Oct 15, 2024

Gilead’s biannual HIV shot reduced risk of infections by 96 percent, company says

The drugmaker said its injections were 89 percent more effective than its own Truvada

The Independent UK · Sep 13, 2024

Is Gilead Sciences Stock Underperforming the Dow?

Despite Gilead Sciences' underperformance relative to the Dow Jones Industrial Average over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart · Sep 5, 2024

Is Gilead Sciences Stock Underperforming the Nasdaq?

Gilead Sciences has recently underperformed the broader Nasdaq Composite, but analysts are reasonably bullish about the stock’s outlook.

Barchart · Jun 18, 2024

3 Dividend Growth Stocks to Buy and Hold

These three dividend-paying growth stocks are worth a look at current levels as the odds rise for Fed rate cuts.

Barchart · Jun 5, 2024

Pharma Firm Urged To Share New 'Game-changer' HIV Drug

More than 300 politicians, health experts and celebrities on Thursday called for US pharmaceutical giant Gilead to allow cheap, generic versions of a promising new HIV drug to be produced so it can reach people in developing countries most affected by the deadly disease.

International Business Times · May 30, 2024

Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?

Gilead Sciences has underperformed the broader market YTD, but Wall Street analysts are still cautiously optimistic about the stock’s prospects.

Barchart · May 14, 2024

Stocks Plunge Before the Open as Meta’s Revenue Forecast Disappoints, U.S. GDP Data and Earnings in Focus

June S&P 500 E-Mini futures (ESM24) are down -0.53%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.87% this morning as a disappointing revenue outlook for the current quarter from Meta weighed on sentiment, while market participants braced for a new round of U.S. economic data and quarterly reports…

Barchart · Apr 25, 2024

Lawsuits Against Gilead Sciences Could Stifle Medical Innovation

Lawsuit against Gilead Sciences raises concerns about innovation impact in drug development and potential implications on future product development.

Top News · Mar 19, 2024

Is Gilead Sciences Stock a Buy Near 52-Week Lows for Its 4% Yield?

Gilead Sciences stock has trailed the broader markets by a significant margin over the last eight years. Is this high-yield dividend stock a good buy right now?

Barchart · Feb 21, 2024